Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05614544 · ClinicalTrials.gov registry record · Phase 1
Dose-Finding and Human Abuse Potential Study Of HSK3486 Injection In Nondependent, Recreational Central Nervous System Depressant Users
A Phase 1 study of General Anesthesia, sponsored by Haisco-USA Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
- 1
- Study location
NCT05614544: Completed Phase 1 study of General Anesthesia, sponsored by Haisco-USA Pharmaceuticals.
NCT05614544 is a Phase 1 study of General Anesthesia that has completed, run by Haisco-USA Pharmaceuticals. The registered enrollment target is 42 participants, below the 1,628-participant average among 4 other General Anesthesia trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05614544, a Phase 1 study of General Anesthesia, has completed, sponsored by Haisco-USA Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
- 1
- Study location
Study Summary
Part 1: To determine the doses of IV HSK3486 and propofol for use in Part 2, the abuse potential part of the study. Part 2: To evaluate the abuse potential of HSK3486 compared with propofol when administered IV to healthy nondependent, recreational CNS depressant drug users.
Primary Outcome
To determine the doses of IV HSK3486 and propofol for use in Part 2, the abuse potential part of the study
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Propofol
- DRUG HSK3486
Study Locations (1)
Utah
- ICON (LPRA) - Salt Lake - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2022-08-16 |
| Est. Completion | 2023-10-03 |
| Phase | Phase 1 |
What the finished NCT05614544 record still lists
NCT05614544 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 42 participants, a relatively small participant target, below the 1,628-participant average among 4 other General Anesthesia trials with a reported enrollment target (97% lower).
The record links to 1 condition, with General Anesthesia appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT05614544 reports a single indexed study location in Utah.
Frequently Asked Questions
What is clinical trial NCT05614544 about?
NCT05614544 is a clinical study titled "Dose-Finding and Human Abuse Potential Study Of HSK3486 Injection In Nondependent, Recreational Central Nervous System Depressant Users". Part 1: To determine the doses of IV HSK3486 and propofol for use in Part 2, the abuse potential part of the study. Part 2: To evaluate the abuse potential of HSK3486 compared with propofol when administered IV to healthy nondependent, recreational CNS depressant drug users.
What is the current status of trial NCT05614544?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2022-08-16. Estimated completion is 2023-10-03.
What conditions does trial NCT05614544 study?
This clinical trial studies the following conditions: General Anesthesia.
What interventions are being tested in trial NCT05614544?
The interventions under investigation include: Placebo (DRUG), Propofol (DRUG), HSK3486 (DRUG).
Who is sponsoring clinical trial NCT05614544?
This trial is sponsored by Haisco-USA Pharmaceuticals, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05614544 being conducted?
This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for General Anesthesia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Monitoring Exhaled Propofol to Individualize General Anesthesia
COMPLETED · Phase 1
-
Risk of Acute Complications With Rocuronium vs Cisatracurium in Patients With Chronic Kidney Disease
RECRUITING · Phase 4
-
The Society for Obstetric Anesthesia and Perinatology Research Network General Anesthesia Registry
RECRUITING
-
Study to Determine if Patients Exposed to General Anesthesia Significant Numbers of Times Would Increase the Risk for Intraoperative Awareness.
ACTIVE NOT RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02852213 · 42 participants · Phase 1
A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients
- NCT03136146 · 42 participants · Phase 2
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
- NCT03178149 · 42 participants · Phase 1
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
- NCT03663530 · 42 participants · NA
Circadian Misalignment and Energy Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI